

Edition : JUIN 2018



- [1] **“Dedifferentiated Solitary Fibrous Tumor: A Concise Review,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [2] **“Aluminum Toxicity: Evaluation of 16-Year Trend Among 14 919 Patients and 45 480 Results,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [3] **“Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [4] **“Malignant Mesothelioma and Its Non-Asbestos Causes,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [5] **“Distribution of 21-Gene Recurrence Scores Among Breast Cancer Histologic Subtypes,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [6] **“Malignant Mesothelioma in Individuals With Nonmesothelial Neoplasms,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [7] **“Radiotherapy for Patients With Resected Tumor Deposit–Positive Colorectal Cancer: A Surveillance, Epidemiology, and End Results–Based Population Study,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [8] **“Ocular Human Papillomavirus Infections,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [9] **“The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus–Associated Head and Neck Squamous Cell Carcinoma,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [10] **“The Role of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [11] **“The Revised College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline: A Step Forward for Molecular Cytopathology,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [12] **“Human Papillomavirus–Related Malignancies in the Setting of Posttransplantation Immunosuppression,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.

- [13] **“The Impact and Burden of Human Papillomavirus–Associated Disease,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [14] **“Challenges of Human Papillomavirus Infection and Associated Diseases in Low-Resource Countries,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [15] **“Human Papillomavirus Infection of the Skin,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [16] **“The Importance of High-Risk Human Papillomavirus Types Other Than 16 and 18 in Cervical Neoplasia,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [17] **“Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States: Is It Time?,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [18] **“Improved Intraoperative Smears,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.
- [19] **“Fetal Vascular Malperfusion,”** *Arch. Pathol. Lab. Med.*, Jun. 2018.

MODERN PATHOLOGY

- [1] **“Low risk of lymph node metastasis in 495 early gastric cardiac carcinomas: a multicenter clinicopathologic study of 2101 radical gastrectomies for early gastric carcinoma,”** *Mod. Pathol.*, May 2018.
- [2] **“Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer,”** *Mod. Pathol.*, May 2018.
- [3] **“DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome,”** *Mod. Pathol.*, Jun. 2018.
- [4] **“The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence,”** *Mod. Pathol.*, May 2018.
- [5] **“Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1,”** *Mod. Pathol.*, May 2018.
- [6] **“Are EWSR1-NFATc2-positive sarcomas really Ewing sarcomas?,”** *Mod. Pathol.*, Jun. 2018.

- [7] **“Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation.”** *Mod. Pathol.*, Jun. 2018.
- [8] **“HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population.”** *Mod. Pathol.*, Jun. 2018.
- [9] **“Colonic graft-vs.-host disease in autologous versus allogeneic transplant patients: earlier onset, more apoptosis, and lack of regulatory T-cell attenuation.”** *Mod. Pathol.*, Jun. 2018.
- [10] **“Using deep convolutional neural networks to identify and classify tumor-associated stroma in diagnostic breast biopsies.”** *Mod. Pathol.*, Jun. 2018.
- [11] **“Mucosal inflammation in Candida esophagitis has distinctive features that may be helpful diagnostically.”** *Mod. Pathol.*, Jun. 2018.

Seminars in Diagnostic Pathology

- [1] **“Iatrogenic pulmonary lesions,”** *Semin. Diagn. Pathol.*, Jul. 2018.
- [2] **“Iatrogenic solid tumors following immunosuppressive therapy,”** *Semin. Diagn. Pathol.*, Jul. 2018.
- [3] **“Drug induced pseudolymphoma,”** *Semin. Diagn. Pathol.*, Jul. 2018.
- [4] **“Iatrogenic lesions of soft tissue and bone,”** *Semin. Diagn. Pathol.*, Jul. 2018.
- [5] **“Reexamining post-transplant lymphoproliferative disorders: Newly recognized and enigmatic types,”** *Semin. Diagn. Pathol.*, Jul. 2018.
- [6] **“Iatrogenic pathology of the urinary bladder,”** *Semin. Diagn. Pathol.*, Jul. 2018.
- [7] **“Iatrogenically false positive sentinel lymph nodes in breast cancer: Methods of recognition and evaluation,”** *Semin. Diagn. Pathol.*, Jul. 2018.
- [8] **“Iatrogenic lesions—Preface,”** *Semin. Diagn. Pathol.*, Jul. 2018.



- [1] **“MDM2 expression in the progression of Barrett’s oesophagus,”** *Histopathology*, Jun. 2018.
- [2] **“Spindle cell-predominant epithelioid fibrous histiocytoma,”** *Histopathology*, Jun. 2018.
- [3] **“Homeobox transcriptional factor engrailed homeobox 1 is expressed specifically in normal and neoplastic sweat gland cells,”** *Histopathology*, Jun. 2018.
- [4] **“Some diffuse large B cell lymphomas (DLBCLs) present with clone-dependent TTF-1 positivity,”** *Histopathology*, Jun. 2018.
- [5] **“Podoplanin-positive myofibroblasts: a pathological hallmark of pleuroparenchymal fibroelastosis,”** *Histopathology*, Jun. 2018.
- [6] **“Primordial odontogenic tumour: report of two cases,”** *Histopathology*, Jun. 2018.
- [7] **“Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells,”** *Histopathology*, Jun. 2018.
- [8] **“Malignant mesothelioma with squamous differentiation,”** *Histopathology*, Jun. 2018.
- [9] **“Amplification of *FRS2* in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases,”** *Histopathology*, Jun. 2018.
- [10] **“Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial,”** *Histopathology*, Jun. 2018.
- [11] **“High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma,”** *Histopathology*, Jun. 2018.
- [12] **“Increased expression of senescence-associated cell cycle regulators in the progression of biliary atresia: an immunohistochemical study,”** *Histopathology*, Jun. 2018.
- [13] **“Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers,”** *Histopathology*, Jun. 2018.

- [14] **“Comparison of dysplastic fundic gland polyps in patients with and without familial adenomatous polyposis,”** *Histopathology*, Jun. 2018.
- [15] **“The pathology of lumbosacral lipomas: macroscopic and microscopic disparity have implications for embryogenesis and mode of clinical deterioration,”** *Histopathology*, Jun. 2018.
- [16] **“Invasion in breast lesions: the role of the epithelial-stroma barrier,”** *Histopathology*, Jun. 2018.
- [17] **“HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas,”** *Histopathology*, Jun. 2018.
- [18] **“Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis,”** *Histopathology*, Jun. 2018.
- [19] **“Comparison of Epstein-Barr virus-positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan,”** *Histopathology*, Jun. 2018.
- [20] **“Organisation of lymphocytic infiltrates in ANCA-associated glomerulonephritis,”** *Histopathology*, Jun. 2018.



Diagnostic Histopathology

- [1] **“Low risk of lymph node metastasis in 495 early gastric cardiac carcinomas: a multicenter clinicopathologic study of 2101 radical gastrectomies for early gastric carcinoma.,”** *Mod. Pathol.*, May 2018.
- [2] **“Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer.,”** *Mod. Pathol.*, May 2018.
- [3] **“DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome.,”** *Mod. Pathol.*, Jun. 2018.
- [4] **“The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence.,”** *Mod. Pathol.*, May 2018.

- [5] **“Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1,”** *Mod. Pathol.*, May 2018.
- [6] **“Are EWSR1-NFATc2-positive sarcomas really Ewing sarcomas?,”** *Mod. Pathol.*, Jun. 2018.
- [7] **“Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprostnastic evaluation.,”** *Mod. Pathol.*, Jun. 2018.
- [8] **“HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population.,”** *Mod. Pathol.*, Jun. 2018.
- [9] **“Colonic graft-vs.-host disease in autologous versus allogeneic transplant patients: earlier onset, more apoptosis, and lack of regulatory T-cell attenuation.,”** *Mod. Pathol.*, Jun. 2018.
- [10] **“Using deep convolutional neural networks to identify and classify tumor-associated stroma in diagnostic breast biopsies.,”** *Mod. Pathol.*, Jun. 2018.
- [11] **“Mucosal inflammation in Candida esophagitis has distinctive features that may be helpful diagnostically.,”** *Mod. Pathol.*, Jun. 2018.

THE AMERICAN JOURNAL OF
SURGICAL PATHOLOGY

- [1] **“Noninferiority Diagnostic Value, but Also Economic and Turnaround Time Advantages From Digital Pathology.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [2] **“Superficial Solitary Fibrous Tumor: A Series of 26 Cases.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [3] **“Differentiated Vulvar Intraepithelial Neoplasia-like and Lichen Sclerosus-like Lesions in HPV-associated Squamous Cell Carcinomas of the Vulva.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [4] **“Fallopian Tube Mucosal Involvement in Cervical Gastric-type Adenocarcinomas: Report of a Series With Discussion of the Distinction From Synchronous In Situ Tubal Lesions.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [5] **“Distinct Genomic Copy Number Alterations Distinguish Mucinous Tubular and Spindle Cell Carcinoma of the Kidney From Papillary Renal Cell Carcinoma With Overlapping Histologic Features.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [6] **“Histopathologic Features of Postablation Tubal Sterilization Syndrome.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [7] **“Inflammatory Myofibroblastic Tumor Associated With the Placenta: Short Tandem Repeat Genotyping Confirms Uterine Site of Origin.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [8] **“Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [9] **“Acral Spitz Nevi: A Clinicopathologic Study of 50 Cases With Immunohistochemical Analysis of P16 and P21 Expression.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [10] **“Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [11] **“Mediastinal Synovial Sarcoma: Clinicopathologic Analysis of 21 Cases With Molecular Confirmation.”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [12] **“Phyllodes Tumor of the Prostate With Epithelial Intestinal Metaplasia.”** *Am. J. Surg. Pathol.*, Jun. 2018.

- [13] **“Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers.,”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [14] **“Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations.,”** *Am. J. Surg. Pathol.*, Jun. 2018.
- [15] **“Fluorescent In Situ Hybridization for TP53 in the Diagnosis of Pediatric Osteogenic Sarcoma.,”** *Am. J. Surg. Pathol.*, Jun. 2018.

- [1] **“Alcohol and Cancer: A Statement of the American Society of Clinical Oncology,”** *J. Clin. Oncol.*, Jan. 2018.
- [2] **“Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update,”** *J. Clin. Oncol.*, Jan. 2018.
- [3] **“Financial Impact of Breast Cancer in Black Versus White Women,”** *J. Clin. Oncol.*, Jun. 2018.
- [4] **“Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma,”** *J. Clin. Oncol.*, Jun. 2018.
- [5] **“MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis,”** *J. Clin. Oncol.*, Jun. 2018.
- [6] **“Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas,”** *J. Clin. Oncol.*, Jun. 2018.
- [7] **“DNA Repair Deficiency and Immunotherapy Response,”** *J. Clin. Oncol.*, Jun. 2018.
- [8] **“Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline,”** *J. Clin. Oncol.*, Jun. 2018.
- [9] **“Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers,”** *J. Clin. Oncol.*, Jun. 2018.
- [10] **“Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study,”** *J. Clin. Oncol.*, Jun. 2018.
- [11] **“Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma,”** *J. Clin. Oncol.*, Jun. 2018.
- [12] **“Keeping Expectations in Check With Immune Checkpoint Inhibitors,”** *J. Clin. Oncol.*, Jun. 2018.

- [13] **“Breaking the Glass Ceiling of Overall Survival in Non–Small-Cell Lung Cancer,”** *J. Clin. Oncol.*, Jun. 2018.
- [14] **“Duration of Anti–Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?,”** *J. Clin. Oncol.*, Jun. 2018.

JAMA Oncology

- [1] **“Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia,”** *JAMA Oncol.*, Jun. 2018.
- [2] **“Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndrome—Reply,”** *JAMA Oncol.*, Jun. 2018.
- [3] **“Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia—Reply,”** *JAMA Oncol.*, Jun. 2018.
- [4] **“Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndrome,”** *JAMA Oncol.*, Jun. 2018.
- [5] **“Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndrome,”** *JAMA Oncol.*, Jun. 2018.
- [6] **“End-of-Life Care Options and Decision Making for Older Patients With Malignant Brain Tumors,”** *JAMA Oncol.*, Jun. 2018.
- [7] **“Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer—Reply,”** *JAMA Oncol.*, Jun. 2018.
- [8] **“Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [9] **“Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [10] **“Possible Underestimation of the Provision of Palliative Care—Reply,”** *JAMA Oncol.*, Jun. 2018.

- [11] **“Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening—Reply,”** *JAMA Oncol.*, Jun. 2018.
- [12] **“Possible Underestimation of the Provision of Palliative Care,”** *JAMA Oncol.*, Jun. 2018.
- [13] **“Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening,”** *JAMA Oncol.*, Jun. 2018.
- [14] **“End-of-Life Care Options and Decision Making for Older Patients With Malignant Brain Tumors—Reply,”** *JAMA Oncol.*, Jun. 2018.
- [15] **“Our Shared Humanity—Music as a Means of Facilitating Conversations on End-of-Life Care,”** *JAMA Oncol.*, Jun. 2018.
- [16] **“Helping Colorectal Cancer Survivors Benefit From Changing Lifestyle Behaviors,”** *JAMA Oncol.*, Jun. 2018.
- [17] **“Incident Cancer in Cancer Survivors—When Cancer Lurks in the Background,”** *JAMA Oncol.*, Jun. 2018.
- [18] **“Tumor Lysis Syndrome,”** *JAMA Oncol.*, Jun. 2018.
- [19] **“Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer—The New Standard of Care?,”** *JAMA Oncol.*, Jun. 2018.
- [20] **“Obesity, Body Composition, and Breast Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [21] **“Some Thoughts on Exposure to the World Trade Center Wreckage and Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [22] **“Precision Medicine and Testing for Tumor Biomarkers—Are All Tests Born Equal?,”** *JAMA Oncol.*, Jun. 2018.
- [23] **“Erythematous Velvety Plaque of the Scrotum and Penis,”** *JAMA Oncol.*, Jun. 2018.
- [24] **“Clinical Trials in Medical Center Advertising,”** *JAMA Oncol.*, Jun. 2018.
- [25] **“Global Cancer Clinical Trials—Cooperation Between Investigators in High-Income Countries and Low- and Middle-Income Countries,”** *JAMA Oncol.*, Jun. 2018.
- [26] **“Targeted Intraoperative Radiation Therapy—A Promising Option for Accelerated Partial Breast Irradiation,”** *JAMA Oncol.*, Jun. 2018.
- [27] **“Physicians’ Compassion, Communication Skills, and Professionalism With and Without Physicians’ Use of an Examination Room Computer,”** *JAMA Oncol.*, Jun. 2018.

- [28] **“Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma,”** *JAMA Oncol.*, Jun. 2018.
- [29] **“Management of Metastatic Melanoma in 2018,”** *JAMA Oncol.*, Jun. 2018.
- [30] **“Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study,”** *JAMA Oncol.*, Jun. 2018.
- [31] **“National Distribution of Cancer Genetic Testing in the United States,”** *JAMA Oncol.*, Jun. 2018.
- [32] **“A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics,”** *JAMA Oncol.*, Jun. 2018.
- [33] **“Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study,”** *JAMA Oncol.*, Jun. 2018.
- [34] **“Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws,”** *JAMA Oncol.*, Jun. 2018.
- [35] **“Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests,”** *JAMA Oncol.*, Jun. 2018.
- [36] **“Malignant Abnormalities in Male *BRCA* Mutation Carriers,”** *JAMA Oncol.*, Jun. 2018.
- [37] **“Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [38] **“Comparison of Laboratory-Developed Tests and FDA-Approved Assays for *BRAF*, *EGFR*, and *KRAS* Testing,”** *JAMA Oncol.*, Jun. 2018.
- [39] **“Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain,”** *JAMA Oncol.*, Jun. 2018.
- [40] **“Estimation of Future Cancer Burden Among Rescue and Recovery Workers Exposed to the World Trade Center Disaster,”** *JAMA Oncol.*, Jun. 2018.
- [41] **“Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [42] **“Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster,”** *JAMA Oncol.*, Jun. 2018.

- [43] **“Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib,”** *JAMA Oncol.*, Jun. 2018.
- [44] **“Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [45] **“Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [46] **“Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer,”** *JAMA Oncol.*, Jun. 2018.
- [47] **“Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis,”** *JAMA Oncol.*, Jun. 2018.
- [48] **“Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act,”** *JAMA Oncol.*, Jun. 2018.

ANNALS OF ONCOLOGY

- [1] **“Letter to the editor on ‘Body mass index and 20-specific cancers—re-analyses of dose-response meta-analyses of observational studies,”** *Ann. Oncol.*, Jun. 2018.
- [2] **“Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene,”** *Ann. Oncol.*, Jun. 2018.
- [3] **“Oral bisphosphonate use and lung cancer incidence among postmenopausal women,”** *Ann. Oncol.*, Jun. 2018.
- [4] **“The hard road to data interpretation: the road is hard too for the patient,”** *Ann. Oncol.*, Jun. 2018.
- [5] **“Functional immune characterization of HIV-associated non-small-cell lung cancer,”** *Ann. Oncol.*, Jun. 2018.

- [6] **“Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer,”** *Ann. Oncol.*, Jun. 2018.
- [7] **“No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3),”** *Ann. Oncol.*, Jun. 2018.
- [8] **“Early evolutionary divergence between papillary and anaplastic thyroid cancers,”** *Ann. Oncol.*, Jun. 2018.
- [9] **“Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification,”** *Ann. Oncol.*, Jun. 2018.
- [10] **“Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer,”** *Ann. Oncol.*, Jun. 2018.
- [11] **“Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study,”** *Ann. Oncol.*, Jun. 2018.
- [12] **“Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer,”** *Ann. Oncol.*, Jun. 2018.
- [13] **“RET fusions in a small subset of advanced colorectal cancers at risk of being neglected,”** *Ann. Oncol.*, Jun. 2018.
- [14] **“Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial,”** *Ann. Oncol.*, Jun. 2018.
- [15] **“Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma,”** *Ann. Oncol.*, Jun. 2018.
- [16] **“Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08),”** *Ann. Oncol.*, Jun. 2018.
- [17] **“Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study,”** *Ann. Oncol.*, Jun. 2018.
- [18] **“Latest clinical evidence and further development of PARP inhibitors in ovarian cancer,”** *Ann. Oncol.*, Jun. 2018.
- [19] **“Further evidence to support judicious use of antibiotics in patients with cancer,”** *Ann. Oncol.*, Jun. 2018.

- [20] **“Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future,”** *Ann. Oncol.*, Jun. 2018.
- [21] **“Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO),”** *Ann. Oncol.*, Jun. 2018.
- [22] **“Methylation in cell-free DNA for early cancer detection,”** *Ann. Oncol.*, Jun. 2018.
- [23] **“Divergent adaptation in thyroid cancers,”** *Ann. Oncol.*, Jun. 2018.
- [24] **“Stringent vaccination of cancer patients: is it that important?,”** *Ann. Oncol.*, Jun. 2018.
- [25] **“Is there a future for EGFR targeted agents in esophageal cancer?,”** *Ann. Oncol.*, Jun. 2018.
- [26] **“RET-fusions: a novel paradigm in colorectal cancer,”** *Ann. Oncol.*, Jun. 2018.
- [27] **“Purchasing silence,”** *Ann. Oncol.*, Jun. 2018.
- [28] **“ARTE and craft of bevacizumab in elderly patients with glioblastoma,”** *Ann. Oncol.*, Jun. 2018.
- [29] **“The allure of ‘ALUR,’”** *Ann. Oncol.*, Jun. 2018.



Leading the way in experimental and clinical research in hematology

- [1] **“Biomarkers predict outcomes for resistant GVHD,”** *Blood*, Jun. 2018.
- [2] **“HHV8-associated lymphoproliferative disorder in the peripheral blood,”** *Blood*, Jun. 2018.
- [3] **“Visceral leishmaniasis presenting with pancytopenia and circulating blastlike lymphocytes,”** *Blood*, Jun. 2018.
- [4] **“Plerixafor effectively mobilizes CD56^{bright} NK cells in blood, providing an allograft predicted to protect against GVHD,”** *Blood*, Jun. 2018.
- [5] **“A common *TCN1* loss-of-function variant is associated with lower vitamin B₁₂ concentration in African Americans,”** *Blood*, Jun. 2018.
- [6] **“MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD,”** *Blood*, Jun. 2018.
- [7] **“Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma,”** *Blood*, Jun. 2018.
- [8] **“Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease,”** *Blood*, Jun. 2018.
- [9] **“High *NPM1* -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML,”** *Blood*, Jun. 2018.
- [10] **“Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies,”** *Blood*, Jun. 2018.
- [11] **“Shielding p53 from destruction,”** *Blood*, Jun. 2018.
- [12] **“Biology and treatment of Richter syndrome,”** *Blood*, Jun. 2018.
- [13] **“iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL,”** *Blood*, Jun. 2018.
- [14] **“TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma,”** *Blood*, Jun. 2018.

- [15] **“TRAIL mediates and sustains constitutive NF- κ B activation in LGL leukemia,”** *Blood*, Jun. 2018.



The NEW ENGLAND
JOURNAL of MEDICINE

- [1] **“Effect of Bronchoconstriction on Airway Remodeling in Asthma,”** *N. Engl. J. Med.*, Jun. 2018.
- [2] **“Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia,”** *N. Engl. J. Med.*, Jun. 2018.
- [3] **“High-Dose Atorvastatin after Stroke or Transient Ischemic Attack,”** *N. Engl. J. Med.*, Jun. 2018.
- [4] **“Extended Antiretroviral Prophylaxis to Reduce Breast-Milk HIV-1 Transmission,”** *N. Engl. J. Med.*, Jun. 2018.
- [5] **“High-Flow Oxygen Therapy in Infants with Bronchiolitis,”** *N. Engl. J. Med.*, Jun. 2018.
- [6] **“Are We Prepared for Nuclear Terrorism?,”** *N. Engl. J. Med.*, Jun. 2018.
- [7] **“Molecular Minimal Residual Disease in Acute Myeloid Leukemia,”** *N. Engl. J. Med.*, Jun. 2018.
- [8] **“Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90.,”** *N. Engl. J. Med.*, Jun. 2018.
- [9] **“Stemming Lung Disease?,”** *N. Engl. J. Med.*, Jun. 2018.
- [10] **“Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts,”** *N. Engl. J. Med.*, Jun. 2018.
- [11] **“Case 19-2018: A 15-Year-Old Girl with Acute Kidney Injury,”** *N. Engl. J. Med.*, Jun. 2018.
- [12] **“Informed Consent and the Role of the Treating Physician,”** *N. Engl. J. Med.*, Jun. 2018.
- [13] **“Nurse-Led Communication in the Intensive Care Unit,”** *N. Engl. J. Med.*, Jun. 2018.

- [14] **“Macular Hole from a Laser Pointer,”** *N. Engl. J. Med.*, Jun. 2018.
- [15] **“Durable Remissions with Ivosidenib in *IDH1* -Mutated Relapsed or Refractory AML,”** *N. Engl. J. Med.*, Jun. 2018.
- [16] **“Migrating *Dirofilaria repens*,”** *N. Engl. J. Med.*, Jun. 2018.
- [17] **“Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss,”** *N. Engl. J. Med.*, Jun. 2018.
- [18] **“Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia,”** *N. Engl. J. Med.*, Jun. 2018.
- [19] **“The Graduate Nurse Education Demonstration — Implications for Medicare Policy,”** *N. Engl. J. Med.*, Jun. 2018.
- [20] **“A Randomized Trial of a Family-Support Intervention in Intensive Care Units,”** *N. Engl. J. Med.*, Jun. 2018.
- [21] **“Growing Ranks of Advanced Practice Clinicians — Implications for the Physician Workforce,”** *N. Engl. J. Med.*, Jun. 2018.
- [22] **“Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy,”** *N. Engl. J. Med.*, Jun. 2018.
- [23] **“Keeping Your Cool — Doing Ebola Research during an Emergency,”** *N. Engl. J. Med.*, Jun. 2018.
- [24] **“Why the VA Needs More Competition,”** *N. Engl. J. Med.*, Jun. 2018.
- [25] **“Subclinical Hyperthyroidism,”** *N. Engl. J. Med.*, Jun. 2018.
- [26] **“A Shocking Turn of Events,”** *N. Engl. J. Med.*, May 2018.
- [27] **“To Fight Burnout, Organize,”** *N. Engl. J. Med.*, Jun. 2018.
- [28] **“Trolleyology and the Dengue Vaccine Dilemma,”** *N. Engl. J. Med.*, Jun. 2018.
- [29] **“Sociogenetic Risks — Ancestry DNA Testing, Third-Party Identity, and Protection of Privacy,”** *N. Engl. J. Med.*, Jun. 2018.
- [30] **“Housing Immigrant Children — The Inhumanity of Constant Illumination,”** *N. Engl. J. Med.*, Jun. 2018.